TRCT
DTIL icon

Tower Research Capital (TRC)’s Precision BioSciences DTIL Stock Holding History

Tower Research Capital (TRC)’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Buy
1,924
+1,736
+923% +$12.2K ﹤0.01% 3776
2026
Q1 		$1.03K Buy
+188
New +$867 ﹤0.01% 4736
2025
Q3 		– Sell
-872
Closed -$3.66K – 5297
2025
Q2 		$3.66K Sell
872
-628
-42% -$3.1K ﹤0.01% 4453
2025
Q1 		$7.16K Sell
1,500
-2,808
-65% -$14.3K ﹤0.01% 3975
2024
Q4 		$16.4K Buy
4,308
+3,839
+819% +$28K ﹤0.01% 3361
2024
Q3 		$4.2K Sell
469
-3,227
-87% -$31.1K ﹤0.01% 4637
2024
Q2 		$36K Buy
3,696
+3,307
+850% +$39K ﹤0.01% 3353
2024
Q1 		$5.28K Buy
+389
New +$4.76K ﹤0.01% 4565
2023
Q4 		– Sell
-969
Closed -$9.91K – 5972
2023
Q3 		$9.91K Buy
969
+780
+413% +$12K ﹤0.01% 4167
2023
Q2 		$2.98K Buy
189
+186
+6,200% +$4.25K ﹤0.01% 5129
2023
Q1 		$0 Sell
3
-352
-99% -$11.6K ﹤0.01% 5901
2022
Q4 		$13K Sell
355
-500
-58% -$19.8K ﹤0.01% 3593
2022
Q3 		$34K Buy
855
+600
+235% +$28.5K ﹤0.01% 3486
2022
Q2 		$12K Buy
255
+147
+136% +$8.63K ﹤0.01% 4275
2022
Q1 		$10K Sell
108
-164
-60% -$22.3K ﹤0.01% 4297
2021
Q4 		$61K Buy
272
+93
+52% +$26K ﹤0.01% 2607
2021
Q3 		$62K Buy
179
+73
+69% +$24.7K ﹤0.01% 2779
2021
Q2 		$40K Sell
106
-88
-45% -$26.4K ﹤0.01% 3203
2021
Q1 		$60K Sell
194
-529
-73% -$185K ﹤0.01% 2968
2020
Q4 		$181K Sell
723
-712
-50% -$175K 0.01% 1797
2020
Q3 		$265K Buy
1,435
+1,163
+428% +$231K ﹤0.01% 2294
2020
Q2 		$68K Buy
272
+237
+677% +$51.9K ﹤0.01% 2797
2020
Q1 		$6K Buy
+35
New +$9.16K ﹤0.01% 2217
2019
Q4 		– Sell
-41
Closed -$10K – 3718
2019
Q3 		$10K Sell
41
-15
-27% -$4.88K ﹤0.01% 2920
2019
Q2 		$22K Buy
+56
New +$22.5K ﹤0.01% 2113

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Tower Research Capital (TRC)'s DTIL Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Precision BioSciences (DTIL) stake by 923% in Q2 2026, buying an estimated $12.2K and bringing the position to 1,924 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3776.

Tower Research Capital (TRC) first reported a position in DTIL in Q2 2019 and has held it in 25 quarters since. The position peaked at $265K in Q3 2020. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Tower Research Capital (TRC) held 1,924 shares of Precision BioSciences worth $15.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,736 Precision BioSciences shares in Q2 2026, an estimated $12.2K.
  • Precision BioSciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3776 holding.
  • Tower Research Capital (TRC) first reported a position in Precision BioSciences in Q2 2019 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Precision BioSciences position peaked at $265K in Q3 2020.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.